Phantom Neuro
Overview
Phantom Neuro is a pioneering neurotechnology company specializing in the development of intuitive neural interfaces that facilitate natural control of prosthetic limbs and robotic exoskeletons. Founded by Dr. Connor Glass, Phantom Neuro operates from Austin, Texas. The company is at the forefront of leveraging advancements in neuroscience, robotics, artificial intelligence, and surgery to transform human-machine interaction. As of 2025, Phantom Neuro has secured approximately $28 million in funding, with significant investment coming from prominent entities such as Blackrock Neurotech, Draper Associates, and Ottobock.
Recent Developments
In recent years, Phantom Neuro has made significant strides in advancing its technological platform and securing vital partnerships and funding:
- April 2025: Phantom Neuro announced a successful $19 million Series A funding round led by Ottobock, a global leader in prosthetics and exoskeletons. This infusion of capital aims to accelerate clinical trials and support the commercialization of its Phantom X platform, which offers intuitive control over prosthetic and robotic devices.
- April 2025: Phantom Neuro received Breakthrough Device and TAP Designations from the U.S. FDA for its flagship Phantom X technology. This recognition positions the company prominently within the neural interface market.
- Jan 2025: A significant milestone was the 94% accuracy achieved in decoding real-time gestures across eleven hand and wrist movements as evidenced by their ASCENT study.
- December 2024: Initiatives were launched for merging implantable medical systems with IoT technology, enhancing device connectivity and extending Phantom Neuro's technological reach.
- May 2024: The company collaborated with Silicon Labs for IoT integration, signifying a move toward more interconnected and sophisticated prosthetic solutions.
- 2023: Phantom Neuro began integrating AI-driven advancements to improve neural interface technology and prosthetic functionality, establishing collaborations with notable tech and medical organizations to further research and development.
- 2022: Launched a partnership with Blackrock Neurotech, which contributes substantially to Phantom X's research and development.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | Data not directly available |
| Headquarters | Austin, Texas, United States |
| Founders | Dr. Connor Glass |
| Revenue | Data not publicly available |
| Profits | Data not publicly available |
| Key Investors | Ottobock, Blackrock Neurotech, Draper Associates |
| Industry | Neurotechnology, Prosthetics, Robotics |
| Number of Employees | Information not available |
Early History
Phantom Neuro emerged from the innovative environment of Johns Hopkins University School of Medicine. Driven by a vision to bridge the gap between human neuromuscular signals and robotic systems, Dr. Connor Glass founded the company with the goal of improving prosthetic functionality and user experience. Early support from academic and biotechnology sectors provided Phantom Neuro the platform to develop its groundbreaking technology, which integrates seamlessly with existing prosthetic systems to enhance mobility and user satisfaction.
Company Profile and Achievements
Phantom Neuro has established itself as a frontrunner in the development of neural interface technology aimed at revolutionizing prosthetic and robotic control. The company’s flagship product, Phantom X, sets a new standard in the industry:
- Phantom X Platform: A neural interface allowing lifelike control of prosthetics and robotic devices, making these extensions of the human body more intuitive and less cognitively taxing.
- FDA Recognitions: Achieved Breakthrough Device and TAP Designations in 2025, highlighting the platform's innovative approach and potential impact.
- Strategic Alliances: Collaborations with leading institutions such as Blackrock Neurotech have accelerated R&D, leading to rapid technological advances and clinical applications.
- Innovative Approach: By integrating IoT with advanced AI, Phantom Neuro's products address long-standing challenges in prosthetic device control, offering users more natural and responsive interactions with their devices.
- Funding and Investment: As of 2025, raised $28 million, underscoring investor confidence in its technology and market potential.
Current Operations and Market Position
Phantom Neuro operates primarily within the neurotechnology and prosthetic markets, focusing on enhancing the interaction between users and their prosthetic devices. With a growing reputation for innovation and reliability, its Phantom X platform leads the industry in intuitive prosthetic control. Through strategic partnerships and aggressive R&D, the company is well-positioned to capture a significant market share, particularly as the demand for advanced prosthetic technology continues to rise globally. The strategic backing of Ottobock further strengthens Phantom Neuro’s market reach and operational capabilities.
Conclusion
Phantom Neuro stands at the cutting edge of neurotechnology, offering transformative solutions for prosthetic limbs control. With robust funding, strategic partnerships, and regulatory achievements, Phantom Neuro is poised to reshape the industry landscape. As it looks to the future, the company's innovative approach promises to deliver more sophisticated and user-friendly robotic systems, ultimately enhancing the quality of life for amputees and individuals requiring prosthetic assistance.